Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?
Butsch
Patrick O
PO
Department of Neurology, Neurology Clinical Trials Unit, Charlestown, MA 02129, USA.
Cudkowicz
Merit E
ME
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D000818:Animals; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic / Q000592:standards; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D009046:Motor Neurons / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism; D013482:Superoxide Dismutase / Q000235:genetics / Q000378:metabolism*; D000072105:Superoxide Dismutase-1
D018696:Neuroprotective Agents; D011956:Receptors, Cell Surface; C000606290:SOD1 protein, human; D004921:Erythropoietin; C000606291:Sod1 protein, mouse; C000606292:Sod1 protein, rat; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1